Medtronic’s Endeavor Stent Hits Primary Endpoint In Pivotal Trial
This article was originally published in The Gray Sheet
Executive Summary
Medtronic's Endeavor zotarolimus-eluting stent is as effective as Boston Scientific's Taxus paclitaxel-eluting stent in the ENDEAVOR IV trial, Medtronic announced July 2
You may also be interested in...
Medtronic Bullish About Endeavor’s Chances In U.S. Market
Medtronic is confident being the late-comer to the U.S. drug-eluting stent market will not hinder its Endeavor zotarolimus-eluting coronary stent gaining market share
Fujifilm Demonstrates Health Specialism With European HealthTech Spinout
From X-ray film in 1936 to the world’s first digital X-ray system in 1983, Fujifilm has a long heritage in medical diagnostics.